Strategies for prevention and management of ocular events occurring with mirvetuximab soravtansine

By sjmartinez • April 27, 2023

Hendershot A, Slabaugh M, Riaz KM, Moore KN, O'Malley DM, Matulonis U, Konecny GE. Strategies for prevention and management of ocular events occurring with mirvetuximab soravtansine. Gynecol Oncol Rep. 2023 Feb 28;47:101155. doi: 10.1016/j.gore.2023.101155. PMID: 37102083; PMCID: PMC10123335.

Tags: Antibody-drug conjugates, Eye care, Folate receptor alpha, Hematology/Oncology, Mirvetuximab soravtansine, Ocular adverse events, ovarian cancer, Publications

Related Posts

Dose-escalated stereotactic body radiotherapy re-irradiation in patients with recurrent head and neck cancer: a prospective phase 2 study using automated non-coplanar volumetric modulated arc therapy

Nikitas J, Ma TM, Cook K, Woods K, Kishan AU, Reddy VK, Hegde JV, John MS, Chai-Ho W, Wong D, Chu FI, Felix C, Tenn[...]

Stereotactic Body Radiation Therapy Utilization Trends for Stage I Non-Small Cell Lung Cancer

Sakowitz S, Tupper HI, Benjamin LN, Oh S, He T, Ronaghi R, Channick CL, Rosenberg BJ, Salehi-Rad R, Smith MI, Bando JM, Young TJ, Barjaktarvic[...]

Liquid Biopsy of Circulating Tumor Cells and DNA in the Context of PSMA Radiopharmaceutical Therapy

Holzgreve A, Mona CE, Kimura K, Li X, Zhu Y, Tseng HR, Lee JK, Drakaki A, Garraway IP, Rettig MB, Calais J, Salavati A. Liquid[...]